NEW YORK (GenomeWeb) – CFD Research Corporation (CFDRC) has acquired the microbiome-based drug discovery division of iXpressGenes (iXG) for an undisclosed amount.
CFDRC and iXpressGenes are both associate companies of the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama.
As part of the acquisition, CFDRC obtained iXG’s high-throughput antimicrobial discovery platform, EMAD (extremophilic microbiome antimicrobial discovery), and all key personnel associated with the division, the companies said.
To read the full story….
…and receive Daily News bulletins.
Already have an account?